Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328123 | 1.00 | GAA (0.54) | GAARAB9AALDH1A1LMNAGLA | |
| Hydrochloric Acid SCHEMBL23152568 | 0.98 | GAA (0.53) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL12308202 | 0.92 | TAS1R3 (0.55) | GAARAB9ACYP26A1TAS1R3TAS1R1 | |
| SCHEMBL12181830 | 0.89 | FNTA (0.54) | ALDH1A1TAS1R3TAS1R1FNTAFNTB | |
| SCHEMBL12635211 | 0.89 | FNTA (0.54) | ALDH1A1TAS1R3TAS1R1FNTAFNTB | |
| SCHEMBL5020131 | 0.86 | CYP26A1 (0.53) | GAARAB9AALDH1A1LMNACTRB1 | |
| SCHEMBL3679721 | 0.85 | RAB9A (0.59) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL5672076 | 0.85 | GAA (0.56) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL10024019 | 0.85 | GAA (0.56) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL8235468 | 0.84 | CA1 (0.56) | GAARAB9AALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041239-B | N- (benzoyl) -L-cysteine methyl ester derivative and preparation method and application thereof | 南方医科大学 | 2020-09-04 | — | — | CN | claimed |
| CN-110041239-A | N- (benzoyl)-L-cysteine methyl esters analog derivative and its preparation method and application | 南方医科大学 | 2019-07-23 | — | — | CN | claimed |
| CN-110041239-B | N- (benzoyl) -L-cysteine methyl ester derivative and preparation method and application thereof | 南方医科大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-110041239-B | N- (benzoyl) -L-cysteine methyl ester derivative and preparation method and application thereof | 南方医科大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-110041239-B | N- (benzoyl) -L-cysteine methyl ester derivative and preparation method and application thereof | 南方医科大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-110041239-A | N- (benzoyl)-L-cysteine methyl esters analog derivative and its preparation method and application | 南方医科大学 | 2019-07-23 | — | — | CN | disclosed |
| CN-110041239-A | N- (benzoyl)-L-cysteine methyl esters analog derivative and its preparation method and application | 南方医科大学 | 2019-07-23 | — | — | CN | disclosed |
| CN-110041239-A | N- (benzoyl)-L-cysteine methyl esters analog derivative and its preparation method and application | 南方医科大学 | 2019-07-23 | — | — | CN | disclosed |
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| CN-102215812-B | Anti-wrinkle agents | POLA CHEM IND INC | 2014-09-10 | — | — | CN | disclosed |
| WO-2012075242-A2 | CONTROLLED CHEMICAL RELEASE OF HYDROGEN SULFIDE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | WO | disclosed |
| CN-102215812-A | Anti-wrinkle agents | POLA CHEM IND INC | 2011-10-12 | — | — | CN | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | GAA 416/4885RAB9A 1266/4885ALDH1A1 3440/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | GAA 416/4885RAB9A 1266/4885ALDH1A1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.